BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion

Alexandra M. Blee, Shujun Liu, Liguo Wang, Haojie Huang

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Prostate cancer (PCa) that becomes resistant to hormone castration and nextgeneration androgen receptor (AR)-targeted therapies, called castration-resistant prostate cancer (CRPC), poses a significant clinical challenge. A better understanding of PCa progression and key molecular mechanisms could bring novel therapies to light. One potential therapeutic target is ERG, a transcription factor aberrantly up-regulated in PCa due to chromosomal rearrangements between androgen-regulated gene TMPRSS2 and ERG. Here we show that the most common PCa-associated truncated ERG T1-E4 (ERGΔ39), encoded by fusion between TMPRSS2 exon 1 and ERG exon 4, binds to bromodomain-1 (BD1) of bromodomain containing protein 4 (BRD4), a member of the bromodomain and extraterminal domain (BET) family. This interaction is partially abrogated by BET inhibitors JQ1 and iBET762. Meta-analysis of published ERG (T1-E4) and BRD4 chromatin immunoprecipitation-sequencing (ChIP-seq) data demonstrates overlap in a substantial portion of their binding sites. Gene expression profile analysis shows some ERG-BRD4 co-target genes are upregulated in CRPC compared to hormone-naïve counterparts. We provide further evidence that ERG-mediated invasion of PCa cells was significantly enhanced by an acetylationmimicking mutation in ERG that augments the ERG-BRD4 interaction. Our findings reveal that PCa-associated ERG can interact and co-occupy with BRD4 in the genome, and suggest this druggable interaction is critical for ERG-mediated cell invasion and PCa progression.

Original languageEnglish (US)
Pages (from-to)38319-38332
Number of pages14
JournalOncotarget
Volume7
Issue number25
DOIs
StatePublished - 2016

Fingerprint

Prostatic Neoplasms
Castration
Exons
Hormones
Chromatin Immunoprecipitation
Androgen Receptors
Transcriptome
Androgens
Genes
Meta-Analysis
Transcription Factors
Therapeutics
Binding Sites
Genome
Light
Mutation
Proteins

Keywords

  • Acetylation
  • BRD4
  • Bromodomain
  • Cell invasion
  • ERG

ASJC Scopus subject areas

  • Oncology

Cite this

BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion. / Blee, Alexandra M.; Liu, Shujun; Wang, Liguo; Huang, Haojie.

In: Oncotarget, Vol. 7, No. 25, 2016, p. 38319-38332.

Research output: Contribution to journalArticle

@article{c0e6805bc36849d78bc52d4fa379a6bd,
title = "BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion",
abstract = "Prostate cancer (PCa) that becomes resistant to hormone castration and nextgeneration androgen receptor (AR)-targeted therapies, called castration-resistant prostate cancer (CRPC), poses a significant clinical challenge. A better understanding of PCa progression and key molecular mechanisms could bring novel therapies to light. One potential therapeutic target is ERG, a transcription factor aberrantly up-regulated in PCa due to chromosomal rearrangements between androgen-regulated gene TMPRSS2 and ERG. Here we show that the most common PCa-associated truncated ERG T1-E4 (ERGΔ39), encoded by fusion between TMPRSS2 exon 1 and ERG exon 4, binds to bromodomain-1 (BD1) of bromodomain containing protein 4 (BRD4), a member of the bromodomain and extraterminal domain (BET) family. This interaction is partially abrogated by BET inhibitors JQ1 and iBET762. Meta-analysis of published ERG (T1-E4) and BRD4 chromatin immunoprecipitation-sequencing (ChIP-seq) data demonstrates overlap in a substantial portion of their binding sites. Gene expression profile analysis shows some ERG-BRD4 co-target genes are upregulated in CRPC compared to hormone-na{\"i}ve counterparts. We provide further evidence that ERG-mediated invasion of PCa cells was significantly enhanced by an acetylationmimicking mutation in ERG that augments the ERG-BRD4 interaction. Our findings reveal that PCa-associated ERG can interact and co-occupy with BRD4 in the genome, and suggest this druggable interaction is critical for ERG-mediated cell invasion and PCa progression.",
keywords = "Acetylation, BRD4, Bromodomain, Cell invasion, ERG",
author = "Blee, {Alexandra M.} and Shujun Liu and Liguo Wang and Haojie Huang",
year = "2016",
doi = "10.18632/oncotarget.9513",
language = "English (US)",
volume = "7",
pages = "38319--38332",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "25",

}

TY - JOUR

T1 - BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion

AU - Blee, Alexandra M.

AU - Liu, Shujun

AU - Wang, Liguo

AU - Huang, Haojie

PY - 2016

Y1 - 2016

N2 - Prostate cancer (PCa) that becomes resistant to hormone castration and nextgeneration androgen receptor (AR)-targeted therapies, called castration-resistant prostate cancer (CRPC), poses a significant clinical challenge. A better understanding of PCa progression and key molecular mechanisms could bring novel therapies to light. One potential therapeutic target is ERG, a transcription factor aberrantly up-regulated in PCa due to chromosomal rearrangements between androgen-regulated gene TMPRSS2 and ERG. Here we show that the most common PCa-associated truncated ERG T1-E4 (ERGΔ39), encoded by fusion between TMPRSS2 exon 1 and ERG exon 4, binds to bromodomain-1 (BD1) of bromodomain containing protein 4 (BRD4), a member of the bromodomain and extraterminal domain (BET) family. This interaction is partially abrogated by BET inhibitors JQ1 and iBET762. Meta-analysis of published ERG (T1-E4) and BRD4 chromatin immunoprecipitation-sequencing (ChIP-seq) data demonstrates overlap in a substantial portion of their binding sites. Gene expression profile analysis shows some ERG-BRD4 co-target genes are upregulated in CRPC compared to hormone-naïve counterparts. We provide further evidence that ERG-mediated invasion of PCa cells was significantly enhanced by an acetylationmimicking mutation in ERG that augments the ERG-BRD4 interaction. Our findings reveal that PCa-associated ERG can interact and co-occupy with BRD4 in the genome, and suggest this druggable interaction is critical for ERG-mediated cell invasion and PCa progression.

AB - Prostate cancer (PCa) that becomes resistant to hormone castration and nextgeneration androgen receptor (AR)-targeted therapies, called castration-resistant prostate cancer (CRPC), poses a significant clinical challenge. A better understanding of PCa progression and key molecular mechanisms could bring novel therapies to light. One potential therapeutic target is ERG, a transcription factor aberrantly up-regulated in PCa due to chromosomal rearrangements between androgen-regulated gene TMPRSS2 and ERG. Here we show that the most common PCa-associated truncated ERG T1-E4 (ERGΔ39), encoded by fusion between TMPRSS2 exon 1 and ERG exon 4, binds to bromodomain-1 (BD1) of bromodomain containing protein 4 (BRD4), a member of the bromodomain and extraterminal domain (BET) family. This interaction is partially abrogated by BET inhibitors JQ1 and iBET762. Meta-analysis of published ERG (T1-E4) and BRD4 chromatin immunoprecipitation-sequencing (ChIP-seq) data demonstrates overlap in a substantial portion of their binding sites. Gene expression profile analysis shows some ERG-BRD4 co-target genes are upregulated in CRPC compared to hormone-naïve counterparts. We provide further evidence that ERG-mediated invasion of PCa cells was significantly enhanced by an acetylationmimicking mutation in ERG that augments the ERG-BRD4 interaction. Our findings reveal that PCa-associated ERG can interact and co-occupy with BRD4 in the genome, and suggest this druggable interaction is critical for ERG-mediated cell invasion and PCa progression.

KW - Acetylation

KW - BRD4

KW - Bromodomain

KW - Cell invasion

KW - ERG

UR - http://www.scopus.com/inward/record.url?scp=84978176815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978176815&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9513

DO - 10.18632/oncotarget.9513

M3 - Article

C2 - 27223260

AN - SCOPUS:84978176815

VL - 7

SP - 38319

EP - 38332

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 25

ER -